Allogenic Adipose Tissue-Derived Stromal/Stem Cells and Vitamin D Supplementation in Patients With Recent-Onset Type 1 Diabetes Mellitus: A 3-Month Follow-Up Pilot Study.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this phase 2 clinical trial publication.

Objective: To evaluate the short term safety and potential therapeutic effect of allogenic adipose tissue-derived stromal/stem cells (ASCs) + cholecalciferol in patients with recent-onset T1D.

Why It Was Studied

Their mean age and disease duration were 26.7 ± 6.1 years and 2.9 ± 1.05 months.

Adverse events were transient headache (n = 8), mild local reactions (n = 7), tachycardia (n = 4), abdominal cramps (n = 1), thrombophlebitis (n = 4), mild floaters (n = 2), central retinal vein occlusion (n = 1, complete resolution).

Who Took Part

The abstract describes 13 patients taking part.

By PubMed's age tags, the people studied were teenagers, young adults and adults, both men and women.

Results: 13 patients were included (8: group 1; 5: group 2).

How the Study Was Run

In design terms this was a pilot study.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

What Was Measured

The subject headings attached to it are Adipose Tissue, Biomarkers, Blood Glucose, Brazil, Cholecalciferol, Combined Modality Therapy and Diabetes Mellitus, Type 1.

Author keywords: adipose tissue-derived stromal/stem cells, pancreatic function, transplant, type 1 diabetes and vitamin D.

What This Means in Plain Language

The paper is a pilot study of Vitamin D, K2, Magnesium and Zinc in 13 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2020 (Frontiers in immunology), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.